Incentive motivation in first-episode psychosis: A behavioural study

Murray, Graham K.; Clark, Luke; Corlett, Philip R.; Blackwell, Andrew D.; Cools, Roshan; Jones, Peter B.; Robbins, Trevor W.; Poustka, Luise
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: It has been proposed that there are abnormalities in incentive motivational processing in psychosis, possibly secondary to subcortical dopamine abnormalities, but few empirical studies have addressed this issue. Methods: We studied incentive motivation in 18 first-episode psychosis patients from the Cambridge early psychosis service CAMEO and 19 control participants using the Cued Reinforcement Reaction Time Task, which measures motivationally driven behaviour. We also gathered information on participants' attentional, executive and spatial working memory function in order to determine whether any incentive motivation deficits were secondary to generalised cognitive impairment. Results: We demonstrated the anticipated "reinforcement-related speeding" effect in controls (17 out of 19 control participants responded faster during an "odd-one-out" task in response to a cue that indicated a high likelihood of a large points reward). Only 4 out of 18 patients showed this effect and there was a significant interaction effect between reinforcement probability and diagnosis on reaction time (F1,35 = 14.2, p = 0.001). This deficit was present in spite of preserved executive and attentional function in patients, and persisted even in antipsychotic medication free patients. Conclusion: There are incentive motivation processing abnormalities in first-episode psychosis; these may be secondary to dopamine dysfunction and are not attributable to generalised cognitive impairment.


Related Articles

  • Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders. van de Kerkhof, Nora W.a.; Fekkes, Durk; van der Heijden, Frank M.M.a.; Egger, Jos I.M.; Verhoeven, Willem M.a. // Neuropsychobiology;Sep2015, Vol. 71 Issue 4, p212 

    Background: Psychosis spectrum disorders, especially schizophrenia, have been linked to disturbed dopaminergic activity in the brain. Plasma homovanillic acid (pHVA) levels partly represent dopaminergic metabolism in the central nervous system. In the present study associations between (changes...

  • Haloperidol.  // AHFS Consumer Medication Information;May2020, p1 

    Haloperidol is used to treat psychotic disorders (conditions that cause difficulty telling the difference between things or ideas that are real and things or ideas that are not real). Haloperidol is also used to control motor tics (uncontrollable need to repeat certain body movements) and verbal...

  • Treatment of Delusions in Dementia with Lewy Bodies – Response to Pharmacotherapy. Fischer, Corinne; Bozanovic, Radenka; Atkins, Jana H.; Rourke, Sean B. // Dementia & Geriatric Cognitive Disorders;2007, Vol. 23 Issue 5, p307 

    Background:Delusions are clinically important symptoms in dementia with Lewy bodies (DLB). The purpose of this review is to examine the level of evidence for treatment of delusions in DLB. Methods:To achieve this objective Medline was searched. Studies were included in the review if they were...

  • Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Patil, Sandeep T.; Lu Zhang; Martenyi, Ferenc; Lowe, Stephen L.; Jackson, Kimberley A.; Andreev, Boris V.; Avedisova, Alla S.; Bardenstein, Leonid M.; Gurovich, Issak Y.; Morozova, Margarita A.; Mosolov, Sergey N.; Neznanov, Nikolai G.; Reznik, Alexander M.; Smulevich, Anatoly B.; Tochilov, Vladimir A.; Johnson, Bryan G.; Monn, James A.; Schoepp, Darryle D. // Nature Medicine;Sep2007, Vol. 13 Issue 9, p1102 

    Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. These pathological features manifest behaviorally as positive symptoms (including hallucinations, delusions...

  • Relationship between insight, educational background and cognition in schizophrenia. Macpherson, Rob; Jerrom, Bill; Hughes, Anthony; Macpherson, R; Jerrom, B; Hughes, A // British Journal of Psychiatry;Jun96, Vol. 168, p718 

    Background: There is a paucity of research into the relationship between insight and variables including cognitive function, educational background and symptomatology in schizophrenia.Method: Sixty-four patients with DSM-III-R diagnosis schizophrenia were assessed with...

  • Caution urged with atypical antipsychotics.  // Medical Journal of Australia;12/3/2012, Vol. 197 Issue 11/12, p605 

    The article warns that commonly prescribed atypical antipsychotics (AAPs), including aripiprazole, olanzapine and quetiapine, lack effectiveness and have a high incidence of adverse effects in middle-aged and older patients with psychotic disorders according to U.S. research.

  • haloperidol:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p103 

    An encyclopedia entry for haloperidol, an antipsychotic drug used primarily to treat schizoprenia and other form of psychoses that has a brand name of Haldol, is presented.

  • Is antipsychotic sensitivity in Alzheimer's disease secondary to abnormal blood-brain barrier integrity? Caravaggio, Fernando; Graff-Guerrero, Ariel // Brain: A Journal of Neurology;Apr2017, Vol. 140 Issue 4, p865 

    No abstract available.

  • Tardive dyskinesia.  // British Medical Journal (Clinical Research Edition);4/18/1981, Vol. 282 Issue 6272, p1257 

    Focuses on tardive dyskinesia. Effects of antipsychotic drugs on the clinical management of psychotic patients; Association of antipsychotic drugs with tardive dyskinesia; Variation in the diagnosis of tardive dyskinesia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics